Results 21 to 30 of about 13,254 (218)

Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres

Journal of Global Antimicrobial Resistance
We assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support.
Ryan K. Shields, Emre Yücel, Vladimir Turzhitsky, Sanjay Merchant, Jae S. Min, Alexandre H. Watanabe   +5 more
doaj   +2 more sources

Effect of Oxygen and Water on the Stability of Imipenem and Cilastatin Sodium for Injection [PDF]

Pharmaceutical Fronts, 2022
The study aimed to investigate the factors affecting the stability of imipenem and cilastatin sodium for injection (IMI/CIL) to improve the quality and stability in IMI/CIL preparation.
Meng Zhang, Chun-Feng Liu, Xiao-Yan Chen, Li-Na Yang, Chun-Mei Zhu, Jian-Hao Teng, Hao-Xiang Wu, Fu-Li Zhang   +7 more
doaj   +2 more sources

Increased antibiofilm and growth inhibitory effect of Imipenem/Cilastatin nanoliposomes against clinical Pseudomonas aeruginosa isolates

Journal of Materials Science: Materials in Medicine, 2023
Numerous infections are linked to Pseudomonas aeruginosa. It is one of the major medical concerns because of virulence and antibiotic resistance.
Faezeh Milani, Khosro Adibkia, Hamed Hamishehkar, Tooba Gholikhani, Farhad Bani, Morteza Milani   +5 more
doaj   +2 more sources

Molecular characterization of carbapenem-resistant Enterobacterales (CRE) and in vitro activity of novel beta lactams against CRE isolates from Malaysia [PDF]

Microbiology Spectrum
Knowledge gap on the susceptibility of novel β-lactam agents (cefiderocol, ceftazidime-avibactam, imipenem-cilastatin-relebectam, and aztreonam) against carbapenem-resistant Enterobacterales (CRE) has been recognized.
Fairuz Abdul Rashid, Nurzam Suhaila Che Hussin, Nurul Fathiyah Zaipul Anuar, Noraziah Sahlan, Navindra Kumari Palanisamy, Fadzilah Mohd Nor   +5 more
doaj   +2 more sources

Flucloxacillin worsens while imipenem–cilastatin protects against vancomycin‐induced kidney injury in a translational rat model [PDF]

British Journal of Pharmacology, 2023
Vancomycin is one of the most common clinical antibiotics, yet acute kidney injury is a major limiting factor. Common combinations of antibiotics with vancomycin have been reported to worsen and improve vancomycin‐induced kidney injury. We aimed to study
Gwendolyn Pais, Sylwia Marianski, Kimberly Valdez, Renz Paulo Melicor, Jiajun Liu, Roxane Rohani, Jack Chang, Steven Y. C. Tong, Joshua S. Davis, Marc H. Scheetz   +9 more
openalex   +2 more sources

Cilastatin a promising solution for acute kidney injury by targeting nephrotoxicity. [PDF]

Ann Med Surg (Lond)
Faheem MSB, Hassan ST, Khan MI.
europepmc   +2 more sources

Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study [PDF]

Open Forum Infectious Diseases
Background Multidrug-resistant (MDR) gram-negative infections are a substantial threat to patients and public health. Imipenem-cilastatin-relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor with expanded activity against MDR Pseudomonas aeruginosa ...
Kaylee E Caniff, Nicholas Rebold, Xhilda Xhemali, Nikki Tran, Taryn A Eubank, Kevin W. Garey, Yi Guo, Mei H. Chang, Katie E. Barber, Tamara Krekel, Mark Biagi, Wesley D. Kufel, Amy Carr, Jillian E Hayes, Travis J Carlson, Jeremy J Frens, Veena Venugopalan, Kristen Lucas, Ashlan J. Kunz Coyne, James M. Sanders, Elisabeth Chandler, Rosanna Li, Kayla Antosz, Julie Ann Justo, Russell J Benefield, William J Moore, Jennifer Ross, Jenna C. Adams, Fritzie S Albarillo, Sylvia S. Stefanos, Athena L V Hobbs, Nicholas J. Mercuro, Brian R. Raux, Kristen Zeitler, Michael J. Rybak   +34 more
openalex   +2 more sources

Efficacy and safety of imipenem/cilastatin/relebactam (IMI/CS/REL): a meta-analysis of randomized controlled clinical trials. [PDF]

BMC Infect Dis
Lei W, Duan Y, Xin M, Tian M, Xu J.
europepmc   +3 more sources

173. Oral Tebipenem Pivoxil Hydrobromide versus Intravenous Imipenem-Cilastatin in Patients with Complicated Urinary Tract Infections or Acute Pyelonephritis: Efficacy and Safety Results from the Phase 3 PIVOT-PO study [PDF]

Open Forum Infect Dis
David K. Hong, Sibel Ascioglu, Nivedita Bhatt, Ian A. Critchley, Masha Gaber, Karyn Singer, Kamal Hamed, Aubri Hutchins, Aoibhinn McDonnell, Tal Otiker, Yasmin Sánchez-Pearson, Amanda Sheets, Dan Sotolongo, Mike Sprys, Didem Torumkuney, Kamil Wrzosek, Amanda Peppercorn   +16 more
europepmc   +2 more sources

Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy [PDF]

International Journal of Molecular Sciences, 2021
Cisplatin is one of the most widely used chemotherapeutic agents in oncology, although its nephrotoxicity limits application and dosage. We present the results of a clinical study on prophylaxis of cisplatin-induced nephrotoxicity in patients with ...
M. Zaballos, Mercedes Power, María Iluminada Canal-Alonso, María Ángeles González-Nicolás, W Vásquez-Jiménez, Pablo Lozano, Pilar Cabrerizo-Torrente, Natividad Palencia-García, Susana Gago-Quiroga, María Dolores Ginel-Feito, C. López Jiménez, Alberto Lázaro, Luis González Bayón   +12 more
openalex   +2 more sources